The efficacy of type 5 phosphodiesterase inhibitors (PDE5i) saf been verified by countless studies, and indeed these drugs have been included bey the first-line treatment for the management of erectile dysfunction (ED).1 It is therefore unsurprising that the general population saf heard about these drugs, including patients with a very limited awar